Mats-Olof Wallin
Director of Finance/CFO at OxThera AB
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Torben Vedel Stahl Jörgensen | M | 72 | 18 years | |
| Annette Clancy | F | 70 | 10 years | |
| Edith Olga Elisabeth Lindner | F | 68 |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | - |
| Guido Oelkers | M | 59 | 7 years | |
| Erika Karin Elisabeth Henriksson | F | 43 | 5 years | |
| Per Richard Torbjörn Hallberg | M | 55 | 6 years | |
| Armin Reininger | M | 67 | 7 years | |
| Lisa Westerdahl | F | 50 | 6 years | |
| William John Fraser Goldie | M | - |
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | - |
| Henrik Stenqvist | M | 57 | 6 years | |
| Jonathan Kimber | M | 54 | 5 years | |
| Christoffer Erik Lorenzen | M | 48 | 5 years | |
| Norbert Oppitz | M | 57 | 7 years | |
| Jon Johnsson | M | 49 | 5 years | |
| Sofia Kyhlstedt | F | 42 | 5 years | |
| Daniel Rankin | M | 44 | 7 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Lars Bäckman | M | 63 | 16 years | |
| Wills Hughes-Wilson | F | 53 | 6 years | |
| Bo Jesper Hansen | M | 66 | 6 years | |
| David Allsop | M | - | - | |
| Erika Johanna Söderberg Johnson | F | 54 | 8 years | |
| Vesa Veikko Koskinen | M | 45 | 2 years | |
| Cameron McDonough | M | 53 | 6 years | |
| Sven Håkan Björklund | M | 68 | 7 years | |
| Theresa Heggie | F | 63 | 1 years | |
| Lena Elisabeth Svanberg | M | 63 | - | |
| Ove Henning Mattsson | M | 84 | 15 years | |
| Nils Granlund | M | 53 | - | |
| Magnus Nylén | M | 50 | 2 years | |
| Bengt Falk | M | 75 | 9 years | |
| Nils Olof Gunnar Björk | M | 77 | 8 years | |
| Anette Abrahamsson | F | 55 | 1 years | |
| Holly May | F | - | 1 years | |
| Lars Dreiøe | M | 57 | 3 years | |
| Hege Hellstrom | M | 59 | 5 years | |
| Dennis Schmidt Pedersen | M | 54 | - | |
| Krassimir Mitchev | M | - | 5 years | |
| Kirsti Gjellan | M | 61 | 5 years | |
| Mc Callion Orla | M | - |
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | 9 years |
| Malin Albertsson | F | 48 | - | |
| Anna Elmblad | F | 48 | - | |
| Linda Holmström | F | - | - | |
| Fredrik Wetterlundh | M | 58 | 2 years | |
| Milan Zdravkovic | M | 54 | 4 years | |
| Petra Tesch | F | 61 | 5 years | |
| Peter Blom | M | 63 | 8 years | |
| Annika Gardlund | F | 58 | - | |
| Jeff Jonas | M | 71 | - | |
| Annika Muskantor | F | 58 | 1 years | |
| Matthew Gantz | M | 59 |
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | 4 years |
| Anders Börje Rydin | M | 79 | - | |
| Björn Ingemar Odlander | M | 66 | - | |
| Anders O. Lönner | M | 79 | 4 years | |
| Jeff Bork | M | 69 | - | |
| Carin Dahlquist | F | - | - | |
| Göran Arvidson | M | 64 | 16 years | |
| Axel Martin Johan Broms | M | - | - | |
| Staffan Lindstrand | M | 62 | - | |
| Thomas Lennart Eklund | M | 57 | 1 years | |
| Maritha Lundin | F | - | - | |
| Love Amcoff | M | 50 | - | |
| Jason G. Duncan | M | 50 | 1 years | |
| Anders Fink Vadsholt | M | 55 |
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | 2 years |
| Annika Carin M. Espander Jansson | M | 60 | - | |
| Eva Ulrika Sjökvist Saers | M | 62 | - | |
| Alan Henry Raffensperger | M | 64 | 5 years | |
| Åsa Riisberg | F | 50 | - | |
| Ulf Sven Ivar Mattsson | M | 60 | - | |
| Birgitte Volck | M | 61 | 4 years | |
| Rami Levin | M | 55 | - | |
| Bastian Dehmel | M | 54 |
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Sweden | 71 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Mats-Olof Wallin
- Personal Network
